E-LIB Suche - Ergebnisse für: Cheng, Ann-Lii

1

Tu1578 IMBRAVE150: EXPLORATORY EFFICACY AND SAFETY RESULTS ..:

Finn, Richard S. ; Breder, Valeriy ; Vogel, Arndt...
Gastroenterology. 166 (2024) 5 - p. S-1738 , 2024

Link: https://doi.org/10.1016/..

2

Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sor..:

Finn, Richard S. ; Galle, Peter R. ; Ducreux, Michel...
Liver Cancer. , 2024

Link: https://doi.org/10.1159/..

3

Changes in Posttreatment Spleen Volume Associated with Immu..:

Chen, Bang-Bin ; Liang, Po-Chin ; Shih, Tiffany Ting-Fang...
Journal of Hepatocellular Carcinoma. 11 (2024) - p. 1015-1029 , 2024

Link: https://doi.org/10.2147/..

4

Outcomes of Post-Immunotherapy Durable Responders of Advanc..:

Liu, Tsung-Hao ; Chen, San-Chi ; Rau, Kun-Ming...
Liver Cancer. , 2024

Link: https://doi.org/10.1159/..

5

Atezolizumab plus bevacizumab for patients with unresectabl..:

Chen, San-Chi ; Tsou, Hsiao-Hui Sophie ; Lee, Teng-Yu...
Journal of Hepatology. 78 (2023) - p. S588-S589 , 2023

Link: https://doi.org/10.1016/..

6

Topoisomerase I Inhibition Radiosensitizing Hepatocellular ..:

Tsai, Chiao-Ling ; Yang, Po-Sheng ; Hsu, Feng-Ming...
Journal of Clinical and Translational Hepatology. 000 (2023) 000 - p. 000-000 , 2023

Link: https://doi.org/10.14218..

7

Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predi..:

Chen, Tom Wei-Wu ; Hsiao, Wen ; Dai, Ming-Shen...
Breast Cancer Research and Treatment. 201 (2023) 3 - p. 377-385 , 2023

Link: https://doi.org/10.1007/..

8

Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevac..:

Kudo, Masatoshi ; Finn, Richard S. ; Cheng, Ann-Lii...
Liver Cancer. 12 (2023) 5 - p. 479-493 , 2023

Link: https://doi.org/10.1159/..

9

Synergistic efficacy of telomerase-specific oncolytic adeno..:

Lin, Zhong-Zhe ; Hu, Mickey C-T ; Hsu, Chiun...
Cancer Letters. 556 (2023) - p. 216063 , 2023

Link: https://doi.org/10.1016/..

10

IMbrave050: Efficacy, safety and patient-reported outcomes ..:

Kaseb, Ahmed ; Chen, Minshan ; Chow, Pierce...
Journal of Hepatology. 78 (2023) - p. S9-S10 , 2023

Link: https://doi.org/10.1016/..

11

Plain language summary of the HIMALAYA study: tremelimumab ..:

Abou-Alfa, Ghassan K ; Lau, George ; Kudo, Masatoshi...
Future Oncology. 19 (2023) 38 - p. 2505-2516 , 2023

Link: https://doi.org/10.2217/..

12

Impact of Bevacizumab Being Skipped due to Adverse Events o..:

Kudo, Masatoshi ; Tsuchiya, Kaoru ; Shao, Yu-Yun...
Liver Cancer. , 2023

Link: https://doi.org/10.1159/..

13

Atezolizumab plus bevacizumab versus active surveillance in..:

Qin, Shukui ; Chen, Minshan ; Cheng, Ann-Lii...
The Lancet. 402 (2023) 10415 - p. 1835-1847 , 2023

Link: https://doi.org/10.1016/..

14

Lenvatinib plus pembrolizumab versus lenvatinib plus placeb..:

Llovet, Josep M ; Kudo, Masatoshi ; Merle, Philippe...
The Lancet Oncology. 24 (2023) 12 - p. 1399-1410 , 2023

Link: https://doi.org/10.1016/..

15

Effects of Early Short-Course Corticosteroids on Immune-Rel..:

Huang, Derek De-Rui ; Liao, Bin-Chi ; Hsu, Wei-Hsun...
Oncology. 102 (2023) 4 - p. 318-326 , 2023

Link: https://doi.org/10.1159/..